Znn3bq.jpeg
²é¿´: 1206  |  »Ø¸´: 4
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

1949stone

ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)

º£Äɰٴ¨

[½»Á÷] New Drugs at FDA ÒÑÓÐ4È˲ÎÓë

New Drugs at FDA


http://www.fda.gov/Drugs/Develop ... ovation/default.htm

New Drugs at FDA: CDER¡¯s New Molecular Entities and New Therapeutic Biological Products
2014 Novel New Drugs Summary

2014 Novel New Drugs Summary (PDF - 13MB)

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA¡¯s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market.

The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development.

Each year, CDER approves a wide range of new drugs and biological products. Some of these products are innovative new products that never before have been used in clinical practice. Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace.

Certain drugs are classified as new molecular entities (¡°NMEs¡±) for purposes of FDA review. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. FDA¡¯s classification of a drug as an ¡°NME¡± for review purposes is distinct from FDA¡¯s determination of whether a drug product is a ¡°new chemical entity¡± or ¡°NCE¡± within the meaning of the Federal Food, Drug, and Cosmetic Act.

Graph symbol View animated charts from the 2014 Novel New Drugs Summary publication on the right. (Not viewable in Internet Explorer version 7 and below.)New Drugs at FDA-1
»Ø¸´´ËÂ¥

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
  • ¸½¼þ 1 : Novel_New_Drugs_2014_Summary.pdf
  • 2015-01-16 10:27:25, 8.55 M

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ò§çïҩѧ Ò©ÎïÑз¢ÖªÊ¶ ËѲØ-¾«-ʵ Ñз¢×¨ÓÃ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

º£Äɰٴ¨Ö¹ÓÚÖÁÉÆ
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
лл·ÖÏí

[ ·¢×ÔСľ³æ¿Í»§¶Ë ]
3Â¥2015-01-17 06:56:20
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 5 ¸ö»Ø´ð

³ô±¿±¿

ľ³æ (ÕýʽдÊÖ)

ÏÈÊÕ²Ø

[ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
4Â¥2015-01-17 15:51:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +9 18815505510 2026-04-09 10/500 2026-04-09 11:46 by Sammy2
[¿¼ÑÐ] ²ÄÁϹ¤³Ì085601£¬270Çóµ÷¼Á +26 @ASDF1234 2026-04-08 27/1350 2026-04-09 10:56 by smile-δÑë
[¿¼ÑÐ] 288Çóµ÷¼Á +15 ûÓдð°¸_ 2026-04-05 15/750 2026-04-09 10:22 by 5268321
[¿¼ÑÐ] 0860004 Çóµ÷¼Á 309·Ö +6 Yin DY 2026-04-09 6/300 2026-04-09 10:19 by °¡Àî999
[¿¼ÑÐ] 0703µ÷¼Á +17 ʰ¾ÁÒ¼ 2026-04-04 19/950 2026-04-09 09:18 by may_ÐÂÓî
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©2£¬²ÄÁÏÓ뻯¹¤308Çóµ÷¼Á +17 ÐܶþÏëÉϰ¶ 2026-04-04 18/900 2026-04-09 09:13 by leyan1127
[¿¼ÑÐ] 308Çóµ÷¼Á +16 ÌÈÈôÆð·çÁËÄØ 2026-04-05 16/800 2026-04-08 23:03 by Öí»á·É
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á +15 a1708 2026-04-06 15/750 2026-04-08 16:23 by luoyongfeng
[¿¼ÑÐ] 264Çóµ÷¼Á +11 ÂóС¶£µ± 2026-04-07 11/550 2026-04-08 16:05 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 275Çóµ÷¼Á +4 1624447980 2026-04-08 5/250 2026-04-08 15:29 by ŶŶ123
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϿƴóÉúÎïѧ297·Ö£¬Çóµ÷¼ÁÍÆ¼ö +8 Y-yyusx 2026-04-06 9/450 2026-04-07 19:38 by biomichael
[¿¼ÑÐ] 081700£¬311£¬Çóµ÷¼Á +17 ¶¬Ê®Èý 2026-04-04 18/900 2026-04-07 12:50 by Sammy2
[¿¼ÑÐ] 293Çóµ÷¼Á +3 ÓÂÔ¶¿â°®314 2026-04-06 3/150 2026-04-07 11:15 by hugr
[¿¼ÑÐ] ¿¼Ñе÷¼Á +7 15615482637 2026-04-04 7/350 2026-04-06 22:56 by chenzhimin
[¿¼ÑÐ] 287Çóµ÷¼Á +3 ͨÐÅѧ˶081000 2026-04-03 4/200 2026-04-06 21:03 by going home
[¿¼ÑÐ] 0854Çóµ÷¼Á +4 assdll 2026-04-05 4/200 2026-04-06 12:29 by ÖзÉÔº¿Õ¹ÜѧԺÑ
[¿¼ÑÐ] Çóµ÷¼Á +10 chenxrlkx 2026-04-05 10/500 2026-04-06 11:31 by Öí»á·É
[¿¼ÑÐ] 296Çóµ÷¼Á +3 Íô£¡£¿£¡ 2026-04-05 5/250 2026-04-05 17:38 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Äܶ¯µ÷¼Á326ר˶ +4 wan112233 2026-04-04 4/200 2026-04-04 22:47 by yu221
[¿¼ÑÐ] 333Çóµ÷¼Á +12 wfh030413@ 2026-04-03 13/650 2026-04-04 21:02 by jj987
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û